3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Sorafenib
42
Bevacizumab
26
Oxaliplatin
21
Radiosurgery
19
Gemcitabine
17
Fluorouracil
15
Hepatectomy
13
lenvatinib
12
Radiofrequency Ablation
11
Nivolumab
11
Cisplatin
11
Radiotherapy
10
Doxorubicin
10
Capecitabine
10
durvalumab
9
Leucovorin
9
Blood Specimen Collection
9
atezolizumab
8
Liver Transplantation
8
Everolimus
7
Electroporation
7
pembrolizumab
6
camrelizumab
6
Sunitinib
6
Immunohistochemistry
6
Cryosurgery
6
Carboplatin
6
tremelimumab
5
sintilimab
5
apatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liver Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled